Koers ESSA Pharma Inc. Toronto S.E.
Aandelen
EPI
CA29668H7085
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 376 mln. 275 mln. 254 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -46 mln. -33,7 mln. -31,05 mln. | Nettowinst (verlies) 2025 * | -72 mln. -52,75 mln. -48,6 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-8,2
x | K/w-verhouding 2025 * |
-6,11
x | Werknemers | 50 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,73% |
Recentste transcriptie over ESSA Pharma Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Parkinson
CEO | Chief Executive Officer | 73 | 24-06-15 |
David Wood
DFI | Director of Finance/CFO | 66 | 01-10-13 |
Peter Virsik
COO | Chief Operating Officer | - | 01-08-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 05-03-15 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 31-07-19 |
Richard Glickman
CHM | Chairman | 65 | 01-10-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,05% | 54,04 mld. | |
+43,57% | 41,96 mld. | |
-1,16% | 41,92 mld. | |
-7,59% | 28,35 mld. | |
+12,49% | 26,35 mld. | |
-22,11% | 19 mld. | |
+7,76% | 13 mld. | |
+28,48% | 12,28 mld. | |
+24,89% | 12,19 mld. |